GlycoMimetics, Inc. (GKO.F)

1,5880 +0,0940 (+6,29%) Börsenschluss: 08:06AM CEST

GlycoMimetics, Inc.

9708 Medical Center Drive
Rockville, MD 20850
United States
240 243 1201
https://www.glycomimetics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 35

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Harout Semerjian	CEO, President & Director	1,05M	N/A	1970
Ms. Rachel K. King	Co-Founder & Director	37,13k	N/A	1959
Mr. Brian M. Hahn	Senior VP & CFO	763,2k	N/A	1974
Dr. Edwin Rock M.D., Ph.D.	Senior VP & Chief Medical Officer	628,85k	N/A	1961
Ms. Stephanie R. Irish CPA	Vice President of Accounting	N/A	N/A	1971
Mr. Christian B. Dinneen-Long	General Counsel & Company Secretary	N/A	N/A	N/A
Mr. Bruce Johnson	Senior VP & Chief Commercial Officer	N/A	N/A	1968
Mr. Chinmaya Rath	Senior VP & Chief Business Officer	N/A	N/A	1977
Mr. Shantha Tyavanagimatt Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Corporate Governance

GlycoMimetics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 7, Vorstand: 6, Shareholderrechte: 9, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.